Histone deacetylase inhibitors: discovery and development as anticancer agents - PubMed (original) (raw)
Review
Histone deacetylase inhibitors: discovery and development as anticancer agents
Paul A Marks et al. Expert Opin Investig Drugs. 2005 Dec.
Abstract
Histone deacetylase (HDAC) inhibitors are a new class of targeted anticancer agents. Several HDAC inhibitors are in clinical trials and have shown significant activity against a spectrum of both haematological and solid tumours at doses that are well tolerated by patients. HDACs and histone acetyltransferases can, by reversible acetylation, modify the structure and function of histones and proteins in transcription factor complexes, which are involved in the regulation of gene expression, as well as many non-histone proteins that are involved in regulating cell proliferation and cell death. HDAC inhibitors are a structurally diverse group of molecules; these agents selectively alter the expression of genes. HDAC inhibitors can induce cancer cell death, whereas normal cells are relatively resistant to HDAC inhibitor-induced cell death.
Similar articles
- Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
Kelly WK, Marks PA. Kelly WK, et al. Nat Clin Pract Oncol. 2005 Mar;2(3):150-7. doi: 10.1038/ncponc0106. Nat Clin Pract Oncol. 2005. PMID: 16264908 Review. - Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
Balakin KV, Ivanenkov YA, Kiselyov AS, Tkachenko SE. Balakin KV, et al. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. doi: 10.2174/187152007781668698. Anticancer Agents Med Chem. 2007. PMID: 17896917 Review. - Chemical origins of isoform selectivity in histone deacetylase inhibitors.
Butler KV, Kozikowski AP. Butler KV, et al. Curr Pharm Des. 2008;14(6):505-28. doi: 10.2174/138161208783885353. Curr Pharm Des. 2008. PMID: 18336297 Review. - Prospects: histone deacetylase inhibitors.
Dokmanovic M, Marks PA. Dokmanovic M, et al. J Cell Biochem. 2005 Oct 1;96(2):293-304. doi: 10.1002/jcb.20532. J Cell Biochem. 2005. PMID: 16088937 Review. - Histone deacetylase inhibitors: latest developments, trends and prospects.
Moradei O, Maroun CR, Paquin I, Vaisburg A. Moradei O, et al. Curr Med Chem Anticancer Agents. 2005 Sep;5(5):529-60. doi: 10.2174/1568011054866946. Curr Med Chem Anticancer Agents. 2005. PMID: 16178777 Review.
Cited by
- Histone deacetylase inhibition enhances antimicrobial peptide but not inflammatory cytokine expression upon bacterial challenge.
Fischer N, Sechet E, Friedman R, Amiot A, Sobhani I, Nigro G, Sansonetti PJ, Sperandio B. Fischer N, et al. Proc Natl Acad Sci U S A. 2016 May 24;113(21):E2993-3001. doi: 10.1073/pnas.1605997113. Epub 2016 May 9. Proc Natl Acad Sci U S A. 2016. PMID: 27162363 Free PMC article. - Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model.
Huang Z, Peng S, Knoff J, Lee SY, Yang B, Wu TC, Hung CF. Huang Z, et al. J Biomed Sci. 2015 Jan 16;22(1):7. doi: 10.1186/s12929-014-0111-1. J Biomed Sci. 2015. PMID: 25591912 Free PMC article. - Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease.
Sung YM, Lee T, Yoon H, DiBattista AM, Song JM, Sohn Y, Moffat EI, Turner RS, Jung M, Kim J, Hoe HS. Sung YM, et al. Exp Neurol. 2013 Jan;239:192-201. doi: 10.1016/j.expneurol.2012.10.005. Epub 2012 Oct 11. Exp Neurol. 2013. PMID: 23063601 Free PMC article. - Inhibition of histone deacetylases in inflammatory bowel diseases.
Glauben R, Siegmund B. Glauben R, et al. Mol Med. 2011 May-Jun;17(5-6):426-33. doi: 10.2119/molmed.2011.00069. Epub 2011 Feb 22. Mol Med. 2011. PMID: 21365125 Free PMC article. Review. - Identification of Compounds That Inhibit Estrogen-Related Receptor Alpha Signaling Using High-Throughput Screening Assays.
Lynch C, Zhao J, Sakamuru S, Zhang L, Huang R, Witt KL, Merrick BA, Teng CT, Xia M. Lynch C, et al. Molecules. 2019 Feb 27;24(5):841. doi: 10.3390/molecules24050841. Molecules. 2019. PMID: 30818834 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources